Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-05-29, Stock:ABBV, The news for the past five days is as follows:
2018-05-21: NEWS1: Roche (RHHBY) Announces Positive Data on Hemophilia Drug.NEWS2: Top Analyst Reports for Procter & Gamble, AbbVie, McDonald&apos;s & PepsiCo.NEWS3: Bristol-Myers Squibb and Three Additional Stocks Under Scanner in the Drug Makers Space.
2018-05-22: NEWS1: Noteworthy Tuesday Option Activity: ABBV, GRA, WSM.NEWS2: Noteworthy Tuesday Option Activity: ABBV, GRA, WSM.NEWS3: Health Care Sector Update for 05/22/2018: VBIV,CTMX,RDY,BMRN.NEWS4: Health Care Sector Update for 05/22/2018: VBIV,CTMX,RDY,BMRN.NEWS5: Health Care Sector Update for 05/22/2018: CTMX,RDY.NEWS6: Health Care Sector Update for 05/22/2018: CTMX,RDY.NEWS7: Vanguard Growth ETF Experiences Big Outflow.NEWS8: Vanguard Growth ETF Experiences Big Outflow.NEWS9: AbbVie Donates $100 Million to Strengthen Access to Healthcare, Housing for Hurricane-Ravaged Puerto Rico.NEWS10: The Zacks Analyst Blog Highlights: Procter & Gamble, AbbVie, McDonald???s and PepsiCo.NEWS11: The Zacks Analyst Blog Highlights: Procter & Gamble, AbbVie, McDonald???s and PepsiCo.NEWS12: The Zacks Analyst Blog Highlights: Procter & Gamble, AbbVie, McDonald???s and PepsiCo.NEWS13: The Zacks Analyst Blog Highlights: Procter & Gamble, AbbVie, McDonald???s and PepsiCo.NEWS14: AbbVie to Present at the Jefferies 2018 Global Healthcare Conference.NEWS15: The Zacks Analyst Blog Highlights: Procter & Gamble, AbbVie, McDonald???s and PepsiCo.
2018-05-23: NEWS1: After Hours Most Active for May 23, 2018 :  GE, F, BAC, MSFT, ABBV, CFG, INTC, CSCO, DCUD, MDLZ, AAPL, AMAT.NEWS2: After Hours Most Active for May 23, 2018 :  GE, F, BAC, MSFT, ABBV, CFG, INTC, CSCO, DCUD, MDLZ, AAPL, AMAT.NEWS3: Analysts Expect 10% Gains Ahead For The Holdings of FTHI.NEWS4: Analysts Expect 10% Gains Ahead For The Holdings of FTHI.NEWS5: Eli Lilly Gets FDA Approval for Taltz in Genital Psoriasis.NEWS6: Eli Lilly Gets FDA Approval for Taltz in Genital Psoriasis.NEWS7: Better Buy: AbbVie Inc. vs. Pfizer Inc..
2018-05-24: NEWS1: AbbVie Is The Amazon Of Biopharma — But Can It Keep Going?.NEWS2: IMBRUVICA® (ibrutinib) Plus GAZYVA® (obinutuzumab) Phase 3 iLLUMINATE Trial for First-Line Therapy of Chronic Lymphocytic Leukemia (CLL) Patients Met Primary Endpoint.NEWS3: Is the Options Market Predicting a Spike in AbbVie (ABBV) Stock?.NEWS4: Wired News – CytomX Gets FDA Approval for Investigational New Drug Application, Triggers $25 Million Milestone Payment from AbbVie.NEWS5: AbbVie Says Phase 3 ILLUMINATE Trial Met Primary Endpoint Of Improvement In PFS.NEWS6: AbbVie Says Phase 3 ILLUMINATE Trial Met Primary Endpoint Of Improvement In PFS.
2018-05-25: NEWS1: After Hours Most Active for May 25, 2018 :  ABBV, KR, QQQ, IBM, V, CPE, LOW, SBUX, QCOM, TXN, CELG, INTC.NEWS2: After Hours Most Active for May 25, 2018 :  ABBV, KR, QQQ, IBM, V, CPE, LOW, SBUX, QCOM, TXN, CELG, INTC.NEWS3: AbbVie's Imbruvica's Phase III Study Meets Primary Endpoint.NEWS4: AbbVie's Imbruvica's Phase III Study Meets Primary Endpoint.NEWS5: AbbVie&apos;s Imbruvica&apos;s Phase III Study Meets Primary Endpoint.NEWS6: Analyzing Ionis’s Q1 Revenue Streams.

Answer: Decrease